Investigational drug · Phase 2
BRY812
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Gynecological Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BRY812"
First trial start
2025
Dec 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BRY812", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Gynecological Malignancies
Largest trials
Live from ClinicalTrials.gov: studies naming "BRY812" as an intervention, largest first.
BioRay Pharmaceutical Co., Ltd.Industry
NCT06038058 · 164 participants (planned) · Start Oct 10, 2023 · Primary completion Aug 2028
Drug: BRY812 for injection · For: Advanced Malignancies
Sites: Guangzhou, China
BioRay Pharmaceutical Co., Ltd.Industry
NCT07311538 · 56 participants (planned) · Start Dec 2025 · Primary completion Dec 2027
Drug: BRY812 for injection · For: Advanced Gynecological Malignancies
Newest research
PubMed records naming it or its code names, newest first.
- Investigation of the cytotoxic effects and mechanisms of the SLC39A6-targeting ADC drug BRY812 in CRC.
Liu X, Liu W, Wu Y, et al. · Sci Rep 2025
Also in development for Advanced Gynecological Malignancies
- SKB518Phase 22 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Advanced Gynecological Malignancies, Lung Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.